Multi-kinase-IN-2

Multi-kinase-IN-2 (compound 7h) 是一种口服有效的血管激酶 (angiokinase) 抑制剂,对包括 VEGFR-1/2/3、PDGFRα/β 和 FGFR-1 在内的血管激酶以及 LYN 和 c-KIT 激酶表现出极好的抑制活性,可显著减弱 AKT 和 ERK 蛋白的磷酸化,诱导细胞凋亡 (apoptosis),并显示出抗癌活性。
产品编号: MS-H41917 CAS No.: 2095628-21-8 分子式: C34H35N5O3 分子量: 561.67
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Multi-kinase-IN-2 (compound 7h) 是一种口服有效的血管激酶 (angiokinase) 抑制剂,对包括 VEGFR-1/2/3、PDGFRα/β 和 FGFR-1 在内的血管激酶以及 LYN 和 c-KIT 激酶表现出极好的抑制活性,可显著减弱 AKT 和 ERK 蛋白的磷酸化,诱导细胞凋亡 (apoptosis),并显示出抗癌活性。

生物实验数据

生物活性 Multi-kinase-IN-2 (compound 7h) is an orally effective angiokinase inhibitor that exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases, significantly attenuates the phosphorylation of AKT and ERK proteins, induces apoptosis, and displays anticancer activity.
IC50 & Target VEGFR2:6.5 ± 0.9 nM, PDGFRβ:9.9 ± 0.7 nM, PDGFRα:7.0 ± 0.1 nM, VEGFR1:31 ± 2.1 nM, VEGFR3:6.3 ± 0.5 nM, FGFR1:23 ± 2.5 nM
体外研究
(In Vitro)

Multi-kinase-IN-2 (compound 7h) (0-10 μM, 14 days) potently inhibits colony formation of HT-29, MKN74, and HepG2 cancer cells.
Multi-kinase-IN-2 (0-3 μM, 24 h) significantly attenuates phosphorylation of AKT and ERK proteins.
Multi-kinase-IN-2 (0-3 μM, 72 h) induces apoptosis of HT-29, MKN74, and HepG2 cell.

Cell Proliferation Assay

Cell Line: HT-29, HepG2, and MKN74 cells
Concentration: 0, 0.2, 0.5, 1, and 2 μM or 0, 0.3, 1, 3, and 10 μM
Incubation Time: 14 days
Result: Exhibited excellent activity in inhibition of colony formations in a dose-dependent manner, with remarkable activity at 1 µM concentration.

Western Blot Analysis

Cell Line: HT-29 and HepG2
Concentration: 0, 0.2, 0.5, 1, and 2 μM or 0, 0.3, 1, 3, and 10 μM
Incubation Time: 24 h
Result: Suppressed the phosphorylation of AKT (Ser473) in a dose-dependent manner with a significant inhibition of ERK (Thr202/Tyr204) phosphorylation at 3 μM.

Apoptosis Analysis

Cell Line: HT-29, MKN74, and HepG2 cells
Concentration: 0, 0.3, 1, and 3 μM
Incubation Time: 72 h
Result: Triggered severe apoptosis of HT-29, MKN74, and HepG2 cells in a dose-dependent manner.
体内研究
(In Vivo)

Multi-kinase-IN-2 (compound 7h) (100 mg/kg, Orally, once daily for 18 days) displays mild inhibition of tumor growth in mice.

Animal Model: Female nu/nu mice (4-6 weeks old, HT-29 human colon cancer xenograft model)
Dosage: 100 mg/kg
Administration: Orally, once daily for 18 days
Result: Displayed mild inhibition of tumor growth, with tumor growth inhibition (TGI) value of 13.39%.

化学信息

分子量 561.67
分子式 C34H35N5O3
CAS No. 2095628-21-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础